Sander Slootweg is the Managing Partner and co-founder of Forbion Capital Partners. See sector focus and contact routes.
Sander Slootweg is the Managing Partner and co-founder of Forbion Capital Partners, having established the Dutch venture capital firm in 2006 after previously co-founding ABN AMRO Capital Life Sciences in 2000. He holds degrees in Business and Financial Economics from the Free University of Amsterdam and Business Administration from Nyenrode University. Forbion’s investment thesis focuses exclusively on life sciences and biotechnology, targeting early-stage companies across Europe with a particular emphasis on the Netherlands and broader European markets. While specific check sizes and lead/follow behavior are not publicly detailed in available sources, Slootweg actively serves on the boards of portfolio companies NorthSea Therapeutics, where he is Chair, and Azafaros. Notable named portfolio companies under his oversight include NorthSea Therapeutics and Azafaros, both of which reflect Forbion’s focus on innovative biotech ventures. In a public interview, Slootweg described Europe as a “fertile ground for life science innovation and investments,” highlighting his conviction in the region’s venture potential. No additional distinctive points of view or publishe
Details on this investor come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist investors in Naarden.
Investors like Sander Slootweg · Full investor directory · Investor access · Company funding database